Vestibular and Auditory Sensory Loss in People with CF
Funding for this trial has been provided in full or in part by Cystic Fibrosis Foundation Therapeutics, Inc.
Number of Participants Being Recruited:
Single / Multi-Center:
STUDY BACKGROUND INFORMATION:
Aminoglycoside antibiotics, such as Tobramycin, can cause inner ear damage resulting in dizziness, vision changes with head motion, motion sickness as well as hearing loss. No previous study has looked at how many CF patients receiving these antibiotics experience symptoms of inner ear damage. This study will include patients with CF who are starting a course of intravenous Tobramycin for a lung infection to test inner ear function during the full length of treatment.
>= 10 Years
P. aeruginosa status:
B. cepacia status:
Other Primary Eligibility Requirements:
Note: Detailed eligibility criteria information may be available on clinicaltrials.gov. If a specific
trial listing for this trial is available, a link to the specific clinicaltrials.gov listing will be present in the "More Information" section below.
The sites listed below are currently recruiting subjects. Please note that this list generally lists either the pediatric or adult program but not both even though both programs may be recruiting subjects. Also, this list does not include sites that may be participating in the study but are not yet open for recruitment. If you are interested in this study please contact your center for more information.
University of Michigan Health System (Pediatric), Ann Arbor, MI, 48109
Kruse, Dawn Phone: (734) 615-3266 Email: email@example.com